Northern Biologics is a great example of the kind of exciting and innovative early-stage company we can build when world-class science comes together with entrepreneurial and seasoned venture capital investors.”
– Northern Biologics CEO Stefan Larson
A collaboration of Toronto-area academic and industry partners including Canadian biotechnology incubator, Blueline Bioscience with the University of Toronto and University Health Network’s Princess Margaret Cancer Centre has announced the creation of a company that could change biotechnology development in Canada.
Northern Biologics is Blueline’s first spin-off biotech company. It hopes to use a selection of antibodies catalogued at U of T and turn them into new therapies for cancer and fibrosis.
More from the Globe and Mail: War chest of discoveries seeds Toronto’s Northern Biologics
Press release from U of T: Northern Biologics to Develop Antibody Therapeutics in Toronto